S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
Free Trial

4D Molecular Therapeutics (FDMT) News Today

→ 3 Sub-$10 Stocks to Buy for 2024 (From TradingTips) (Ad)
Free FDMT Stock Alerts
$25.26
+0.48 (+1.94%)
(As of 10:39 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
insidertrades.com logoInsider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells 1,750 Shares of Stock
insidertrades.com - April 19 at 6:53 AM
marketbeat.com logoVontobel Holding Ltd. Invests $2.89 Million in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
marketbeat.com - April 19 at 5:37 AM
marketbeat.com logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 1,750 Shares
marketbeat.com - April 18 at 9:13 PM
msn.com logo4D Molecular Therapeutics (FDMT) Price Target Increased by 5.81% to 53.24
msn.com - April 17 at 6:20 PM
marketbeat.com logo4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 2.3%
marketbeat.com - April 17 at 11:58 AM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up After Analyst Upgrade
americanbankingnews.com - April 17 at 5:16 AM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Trading 2.5% Higher After Analyst Upgrade
americanbankingnews.com - April 17 at 1:08 AM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Receives New Coverage from Analysts at Barclays
americanbankingnews.com - April 16 at 3:58 AM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Increased to $40.00 by Analysts at Royal Bank of Canada
americanbankingnews.com - April 16 at 3:58 AM
marketbeat.com logoRoyal Bank of Canada Increases 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $40.00
marketbeat.com - April 15 at 1:39 PM
markets.businessinsider.com logoRBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
markets.businessinsider.com - April 15 at 12:21 PM
marketbeat.com logoShort Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Expands By 9.6%
marketbeat.com - April 15 at 11:57 AM
marketbeat.com logo4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up to $26.35
marketbeat.com - April 15 at 10:57 AM
marketbeat.com logo4D Molecular Therapeutics (NASDAQ:FDMT) Now Covered by Barclays
marketbeat.com - April 15 at 8:16 AM
marketbeat.com logoDekaBank Deutsche Girozentrale Invests $966,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
marketbeat.com - April 15 at 5:16 AM
marketbeat.com logoVanguard Group Inc. Trims Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
marketbeat.com - April 14 at 4:16 AM
investing.com logo4D Molecular Therapeutics Inc (FDMT)
investing.com - April 12 at 12:44 AM
marketbeat.com logo4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 4.1%
marketbeat.com - April 9 at 2:46 PM
insidertrades.com logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $259,102.34 in Stock
insidertrades.com - April 4 at 6:36 AM
finance.yahoo.com logo4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares
finance.yahoo.com - April 4 at 2:00 AM
marketbeat.com logoBMO Capital Markets Trims 4D Molecular Therapeutics (NASDAQ:FDMT) Target Price to $63.00
marketbeat.com - April 1 at 1:38 PM
marketbeat.com logo4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 7.5% on Insider Selling
marketbeat.com - April 1 at 12:23 PM
marketbeat.com logo4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Raised to $58.00
marketbeat.com - April 1 at 11:08 AM
marketbeat.com logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of "Moderate Buy" by Brokerages
marketbeat.com - April 1 at 4:15 AM
insidertrades.com logoScott Bizily Sells 5,833 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock
insidertrades.com - March 31 at 5:22 AM
finance.yahoo.com logo4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares
finance.yahoo.com - March 29 at 9:08 PM
marketbeat.com logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 5,833 Shares
marketbeat.com - March 29 at 6:40 PM
markets.businessinsider.com logoOptimistic Outlook for 4D Molecular Therapeutics Ahead of Regulatory Update on CF Gene Therapy 4D-710
markets.businessinsider.com - March 29 at 11:07 AM
globenewswire.com logo4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
globenewswire.com - March 28 at 8:00 AM
marketbeat.com logo4D Molecular Therapeutics (NASDAQ:FDMT) Reaches New 1-Year High at $35.72
marketbeat.com - March 27 at 3:23 PM
insidertrades.com logoScott Bizily Sells 1,750 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock
insidertrades.com - March 21 at 10:32 AM
marketbeat.com logoTrexquant Investment LP Purchases Shares of 44,443 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
marketbeat.com - March 9 at 5:18 AM
marketbeat.com logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Brokerages
marketbeat.com - March 7 at 3:38 AM
globenewswire.com logo4DMT to Participate in Upcoming Investor Conferences
globenewswire.com - March 4 at 8:00 AM
finance.yahoo.com logo4D Molecular Therapeutics Full Year 2023 Earnings: Misses Expectations
finance.yahoo.com - March 2 at 2:50 PM
finance.yahoo.com logo4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results
finance.yahoo.com - March 2 at 8:28 AM
marketbeat.com logoHC Wainwright Reaffirms Buy Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
marketbeat.com - March 1 at 8:29 AM
globenewswire.com logo4DMT Reports Full Year 2023 Financial Results and Operational Highlights
globenewswire.com - February 29 at 4:05 PM
msn.com logo4D Molecular Therapeutics (FDMT) Price Target Increased by 47.68% to 50.55
msn.com - February 24 at 10:54 PM
benzinga.com logo4D Molecular Therapeutics Stock (NASDAQ:FDMT) Dividends: History, Yield and Dates
benzinga.com - February 23 at 5:47 AM
marketbeat.com logoRafferty Asset Management LLC Sells 35,869 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
marketbeat.com - February 22 at 6:20 AM
marketbeat.com logoBarclays PLC Has $941,000 Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
marketbeat.com - February 21 at 4:13 AM
markets.businessinsider.com logoBuy Rating on 4D Molecular Therapeutics Backed by Strong Clinical Results and Broad Commercial Prospects
markets.businessinsider.com - February 13 at 11:57 AM
finance.yahoo.com logoInstitutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth
finance.yahoo.com - February 12 at 9:12 AM
finance.yahoo.com logo4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
finance.yahoo.com - February 12 at 9:12 AM
msn.com logo4D Molecular Therapeutics Secures Major Financial Deal
msn.com - February 10 at 8:51 AM
marketbeat.com logo4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 9.4%
marketbeat.com - February 9 at 4:31 PM
marketbeat.com logo4D Molecular Therapeutics, Inc. Forecasted to Post Q4 2023 Earnings of ($0.39) Per Share (NASDAQ:FDMT)
marketbeat.com - February 9 at 6:28 AM
msn.com logoGoldman reinstates buy rating on 4D Molecular, cites upcoming catalysts
msn.com - February 8 at 7:18 PM
marketbeat.com logo4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down After Insider Selling
marketbeat.com - February 8 at 10:39 AM
Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

Uncover this 2024 Hidden Gem (Ad)

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

FDMT Media Mentions By Week

FDMT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FDMT
News Sentiment
▼
0.73

0.52
▲
Average
Medical
News Sentiment

FDMT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FDMT Articles
This Week
▼
19

2
▲
FDMT Articles
Average Week

Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:FDMT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research